On April 5, 2024, the 2024 AACR present the updated data from a Phase 2 expansion cohort for patients (pts) with advanced NSCLC.

On April 5, 2024, the final results of the first-in-human study of the porcupine (PORCN) inhibitor zamaporvint (RXC004) in patients with advanced solid tumors were reported in 2024 AACR.

On April 7, 2024, the latest clinical data of ociperlimab + tislelizumab + cCRT in patients with untreated limited-stage SCLC was reported in 2024 AACR.

On April 5, 2024, the first in human clinical trial of NXP-800 was reported in 2024 AACR.

The EU's pharmaceutical regulatory system is a complex, multi-layered network with various agencies working together to safeguard the safety, efficacy, and quality of medicines in the European Economic Area.

On April 5, 2024, the latest clinical findings of IMM27M were unveiled at the 2024 AACR, demonstrating its potential effect and setting the stage for subsequent investigations.

On April 5, 2024, the first-in-human phase I study of CTX-712 in patients with advanced, relapsed or refractory malignant tumors (CTX-712-CL-01 study) was reported in 2024 AACR.

On April 7, 2024, the latest clinical data of Cadonilimab (the PD-1/CTLA-4 bispecific antibody) plus chemo were reported in 2024 AACR.

On April 5, 2024, the latest clinical trial of Atezolizumab (atezo) after definitive local therapy vs placebo in patients (pts) with high-risk LA SCCHN were reported in 2024 AACR.

On April 5, 2024, the AACR reported the latest clinical trial results of ASKC202, illustrating its potential clinical benefits and setting the stage for further exploration.

In this article, we will focus on Sosei Heptares, a leading company in the field of GPCR new drug development, and its GPCR research and development pipeline.

This piece will highlight GPCR targets and notable pipelines from Chugai, UCB, Ascendis, and BridgeBio at the 2024 JP Morgan Healthcare Conference.